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DDAVP stopped active gingival bleeding and increased factor VIII level
in moderate haemophilia A: A case report
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Abstract
DDAVP infusion was used as an initial treatment for a 3-year-old moderate haemophilia A
boy with baseline FVIII: C level at 1.5%. With a single dose of 0.3 μg/kg of DDAVP in accompany with
intravenous tranexamic acid, gingival bleeding was immediately stopped without further blood
component or factor VIII concentrate administration. This observation supports DDAVP role to manage
acute bleeding episode in moderate severity haemophilia A.
Key words: Moderate haemophilia A, DDAVP, Gingival bleeding
รายงานผ ูปวย  / Case report
Journal of Medicine and Health Sciences (Vol.15 o.2 ugust 2008)
Sakara Hutspardol
Department of Paediatrics, Faculty of Medicine,
Srinakharinwirot University
62 moo 7 Ongkharak, Nakhon Nayok 26120, Thailand.
Journal of Medicine and Health Sciences
Faculty of Medicine, Srinakharinwirot University
(Vol.15 No.2 August 2008)82
รายงานผ ูปวย: การใหยา DDAVP ทางหลอดเลือดดํา เพ่ือหยุดเลือด
ออกจากเหงือกและเพ่ิมระดับแฟคเตอรแปดในเลือดของ
ผ ูปวยเด็กโรคฮีโมฟเลีย เอ ชนิดรุนแรงปานกลาง
สะการะ หัศภาดล, ปติพร ศิริพัฒนพิพงศ, สุมิตรา วัฒนาธิษฐาน
ภาควิชากุมารเวชศาสตร คณะแพทยศาสตร มหาวิทยาลัยศรีนครินทรวิโรฒ
บทคัดยอ
ผ ูปวยเด็กชายไทยอายุ 3 ป ซึ่งไดรับการวินิจฉัยดวยโรคฮีโมฟเลีย เอ ชนิดรุนแรงปานกลางมีอาการ
เลือดออกมากที่บริเวณเหงือกตามหลังภาวะเหงือกอักเสบ ไดรับการรักษาดวยยา DDAVP ทางหลอดเลือด
ดําในขนาด 0.3 ไมโครกรัมตอน้ําหนักตัวเปนกิโลกรัมเพียงคร้ังเดียว สามารถหยุดเลือดออกที่เหงือกได นอก
จากนีย้งัตรวจพบวาคาการแข็งตวัของเลือด ไดแก APTT ส้ันลงอยางมาก และระดบัของแฟคเตอรแปดในเลือด
(FVIII: C) เพ่ิมข้ึนจากรอยละ 1.5 เปนรอยละ 7.8 โดยไมจําเปนตองไดรับแฟคเตอรแปดชนดิเขมขนหรือสวน
ประกอบของเลือดใดๆ ผลสําเร็จในการหยดุเลือดออกภายหลังการรักษาดวยยา DDAVP แสดงใหเห็นวา ยา
DDAVP อาจเปนอีกทางเลือกหนึ่งของการรักษาอาการเลือดออกจากเยื่อบุในผ ูปวยโรคฮีโมฟเลีย เอ ชนิด
รุนแรงปานกลางได
                                 Journal of Medicine and Health Sciences
                      Faculty of Medicine, Srinakharinwirot University
                                                        (Vol.15 No.2 August 2008) 83
Case report
A 3-year-old Thai boy presented to the
hospital with active gingival bleeding for 24
hours. His mother stated that an amount of
fresh blood loss was in approximately one-
hundred milli l iters. Two days prior to
admission, he complained of pain and
swelling at the gingival. He was given oral
amoxycillin by a local doctor for the treatment
of acute gingivitis. His mother refused any
history of traumatic injury at mouth and face
but she recalled when this patient was 5-
month-old he has had some bleeding through
one side of his ear which rapidly stopped
after external compression. He is the fourth
child of the family which has no known
hereditary bleeding disorder among other
family members. From the physical examina-
tion, an active bleeding site was from the right
upper molar gum. No bruisings, ecchymoses,
petichial rashes, haemarthroses, nor joint
deformities presented in otherwise examina-
tion. For the initial coagulation tests, platelet
count was 236,000/ mL and APTT, PT, TT,
bleeding time, and venous clotting time (VCT)
were 55 sec (21.5-29.1 sec), 11 sec (9.5-13.5
sec), 13 sec (13-15 sec), 3 min (2.5-9 min),
and 17 min (< 15 min), respectively. Factor
VIII (FVIII: C) activity, factor IX (FIX),ristocetin
cofactor activity (RisCof), and von Willebrand
factor antigen (VWF: Ag) were 1.5 unit/mL,
61.1%, 61.3%, and 45%, subsequently.
Local compression with gauze pack was
performed at
the molar. Meanwhile, tranexamic acid was
administered intravenously at doses of 10 mg/
kg every 6 hours. Intravenous desmopressin
(DDAVP) was slowly given at the dose of 0.3
μg/kg to avoid the use of factor VIII concen-
trate or cryoprecipitate replacement therapy.
The coagulation tests including APTT, FVIII:
C, RisCof and VWF: Ag were repeated at 0,
15 min, 30 min, 1 hour, and 4 hours after
DDAVP infusion.
After a dose of DDAVP infusion, the
APTT value of 36.6 sec was achieved at 1
hour. FVIII: C, RisCof, and VWF: Ag were
increased from 1.5 unit/mL, 61.3%, and 45%
to 7.8 unit/mL, 136.4%, and 139.4% after 1
hour of DDAVP infusion, respectively (Table
1)
Bleeding was reduced gradually and
completely ceased at 4 hours after DDAVP
administration. Hemoglobin was stable at 11.3
g/dL without red cell, factor concentrate or
blood component transfusion. During 2 days
of admission, penicill in G sodium was
administered intravenously at 50,000 unit/kg
6 hourly for gingivitis.
After the hospital discharge, this
patient was continued with oral tranexamic
acid. Likewise, penicillin G sodium was
switched to liquid amoxycillin for the total of
7-days course of antibiotics. At his return to
clinic in one week later, no bleeding was
observed by dentist and his gingivitis was
healed.
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Table 1.   Result of coagulation test before and after DDAVP infusion
Test 0 min 15 min 30 min 1 hr  4 hr 
APTT (sec) 55.0 44.0 40.6 36.6 41.8 
FVIII:C (unit/mL) 1.5 2.4 7.0 7.8 7.1 
RisCof (%) 61.3 81.8 126.7 136.4 64.4 




vasopressin or DDAVP) is a synthetic analogue
of vasopressin which was initially used for the
treatment of diabetes insipidus. Intravenous
and nasal administration of DDAVP raise
factor VIII (FVIII) and von Willebrand factor
(VWF) in plasma owing to a release of these
two factors from endothelial storage pool.
DDAVP has been used successfully in the
prevention and treatment of bleeding in mild
haemophilia A and von Willebrand disease
type I and II at the dose of 0.3 μg/kg
intravenous infusion for at least 20 minutes1-3.
DDAVP is efficacious as a haemostatic agent
not only in haemophilia or von Willebrand
disease, but also in patients with acquired
platelet dysfunctions for example in uraemia
and salicylate intake.
DDAVP has no proven benefit in
patients with moderate or severe haemophilia
A because of no specifically designed study
to investigate the responsiveness in terms of
FVIII increment and consistent response after
repeated infusions. However, several published
reports for DDAVP use in mild to moderate
haemophilia A revealed a promising response
to slow down bleedings4-6.Rodeghiero F and
co-workers have demonstrated that FVIII: C
increase is sufficiently consistent in patients
with mild or moderate haemophilia A after a
DDAVP test-infusion7. However, higher FVIII:
C baseline without an evidence of bleeding
symptom in this reference cannot entirely
support DDAVP role to stop a bleeding
instance in moderate hemophiliacs.
Although, the response to increase
FVIII and VWF level and to stop bleeding after
DDAVP infusion is well-recognized, is also very
important to perform a test-infusion as a guide
for the future use of each individual patient.
Moreover, factor VIII concentrate should be
already prepared for an unsatisfactory
response post DDAVP infusion. Nevertheless,
the prospective study to evaluate DDAVP
response together with the clinical relevance
in other presentations of bleeding should be
performed in moderate or severe haemophilia
A.
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Summary
Desmopressin (DDAVP) is commonly
used to stop bleeding in only patients with mild
haemophilia A and von Willebrand disease
type I and II. Very little information supports
DDAVP effectiveness in moderate and
severehaemophilia A due to an insufficient
increment of factor VIII (FVIII) and von
Willebrand factor (VWF). This case report
showed that intravenous DDAVP infusion was
able to increase FVIII:C, RisCof, and VWF:Ag
and to stop active gingival bleeding in a
patient with haemophilia A in moderate
severity .
It also suggests that DDAVP may be
an alternative initial remedy for controlling of
superficial bleeding such as active gingival
bleeding in moderate haemophilia A instead
of immediately giving factor VIII concentrate
or blood component replacement therapy.
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